Trials / Completed
CompletedNCT01147484
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor negative.
Detailed description
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Foretinib | foretinib, at a continuous oral daily dose of 60 mg |
Timeline
- Start date
- 2010-09-02
- Primary completion
- 2014-12-14
- Completion
- 2015-02-13
- First posted
- 2010-06-22
- Last updated
- 2023-08-04
Locations
9 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01147484. Inclusion in this directory is not an endorsement.